Page 46 - Bio Developments News Today

Second Vir-GSK monoclonal antibody to enter Phase 1/2 COVID-19 trials Vir Biotechnology and GSK will evaluate VIR-7832 in the early treatment of COVID-19 in a Phase 1b/2a trial starting in the first quarter of this year. Preclinical data suggests VIR-7832, a neutralising COVID-19 antibody, has two distinguishing properties: an enhanced ability to clear infected cells and the potential to enhance virus-specific T cell function, which could help treat and/or prevent CO...

Samsung Biologics is aiming to become ‘a full-service biopharmaceutical company’: creating a greater global footprint for its CDMO business, continuing to advance its biosimilars business, and laying the groundwork for novel drug development. Speaking at the 29 th​ annual JP Morgan Healthcare Conference yesterday, John Rim – who took on the reins as CEO last month – unveiled the South Korean companys growth plans. In 2021 it will speed up construction of i...

Baxter BioPharma Solutions sterile manufacturing agreement with Novavax will help increase commercial production of the vaccine in Europe and the UK. Manufacturing services for NVX-CoV2373 will take place at Baxter’s state-of-the-art facility in Halle/Westfalen, Germany. The site has broad sterile manufacturing capabilities, offers current good manufacturing practices (cGMP) manufacturing and is designed to deliver products with optimum efficiency and speed to mar...

New antibody discovery platform could help accelerate CAR-T therapeutic development In a paper published in the Journal of Biological Chemistry​​​, OXGENE scientists used the self-labelling integral membrane (SLIM) protein discovery system to identify a panel of novel antibodies against the oncogenic target epithelial cell adhesion molecule, which remained in its native configuration within the cell membrane. They said they were able to further demonstrate the functionality of these anti...

Codagenix’s intranasal COVID-19 vaccine has entered Phase 1 clinical trials: with the first volunteers dosed in the UK.

Moderna to run three new infectious disease vaccine development programs, EU vaccine distribution begins Moderna announced today that it is expanding its pipeline of innovative vaccines with three new development programs based on the clinical success of its infectious disease vaccine portfolio to date. Those programs cover mRNA vaccine candidates against seasonal flu, HIV and the Nipah virus. The US biotech also announced an expansion of its respiratory syncytial ...